Civitas Therapeutics Inc., a new spinout from Alkermes Inc., is off to a good start with $20 million in Series A financing from its founding investor Longitude Capital and co-lead Canaan Partners. Civitas, of Chelsea, Mass., is born of Alkermes' pulmonary delivery technology with pipeline assets and commercial-ready manufacturing facilities. Alkermes retains a significant equity position in the new biotech.